|
SAS launches drug development 3.0
SAS has announced the launch of SAS Drug Development 3.0,
which is based on the SAS 9 platform. This latest version provides a centralised
repository that allows life science firms to analyse their clinical research
for regulatory submission. Features such as exploring newer market opportunities,
product-line extensions and safety issues within a controlled and collaborative
framework are designed specifically for research industries and life sciences.
The Indian clinical research industry is valued at over $100 million, and is
witnessing a growth rate of 80 percent. Says Sudipta Sen, MD and CEO, SAS India,
“SAS Drug Development 3.0 is aimed at tapping this fast-growing segment.
Indian pharmaceutical companies are gearing up to figure out innovative ways
to effectively manage, analyse and explore massive amounts of data, and at the
same time minimise their time to market. It provides an integrated system for
managing, analysing, reporting and reviewing clinical research information.”
According to him, this solution will allow companies to increase revenues, enhance
productivity of the clinical research team and improve clinical programme investment
decisions in an environment that facilitates regulatory compliance.
It allows users to access research and clinical data that is scattered in silos
across different departments on incompatible systems, and then integrate the
data in a cost-effective manner.
|
